Our goal is to make biological drugs accessible

Biological drugs have revolutionized the treatment of many serious diseases such as cancer, rheumatoid arthritis, psoriasis and macular degeneration. The only problem is that they are so expensive that only a fraction of those affected can be treated with them. Our goal is to make biological drugs accessible to everyone who needs them.

We strive towards the lowest possible production cost

We base the development of our Biosimilars on the patented platform technology that can provide up to 12 times productivity and thereby up to an 80% cost reduction compared to standard systems in the development of biological drugs.

We are building a world-leading biosimilar developer

We develop biosimilars in treatment of macular degeneration ( Xlucane™), rheumatoid arthritis and psoriasis (BIIB801) and cancer (Xdivane™) addressing originator sales of over SEK 100 billion




Patents and patent applications


Biosimilars under development

Capital Markets Day 22 September, 2022

Capital Markets Day 17 May, 2021

At Xbrane Biopharma

Press Releases

19 Sep 2022

By reason of the imminent launch of Ximluci® in Europe, Xbrane Biopharma AB invites to a Capital Markets Day on September 22, 2022

16 Sep 2022

STADA and Xbrane welcome EMA positive opinion for ranibizumab biosimilar candidate Ximluci

07 Sep 2022

Welcome to Xbrane’s Capital Markets Day, including a unique visit to the new research lab, on September 22, 2022

24 Aug 2022

Invitation to Xbrane’s presentation at the Redeye Late-Stage Life Science Event

22 Jul 2022

Xbrane Biopharma releases interim report for January – June 2022

20 Jul 2022

Invitation to presentation of Xbrane Biopharma’s interim report January – June 2022 on July 22, 2022

04 Jul 2022

Xbrane provides update on ranibizumab biosimilar candidate FDA filing

30 Jun 2022

Xbrane Biopharma AB (“Xbrane” or the “Company”) announces changes to the number of shares and votes in the Company.

17 Jun 2022

Members of Xbrane’s management team sell shares to pay taxes but remain dedicated and long-term employees and shareholders